Turner, RC and Holman, RR and Cull, CA and Stratton, IM and Matthews, DR and Frighi, V and Manley, SE and Neil, A and McElroy, K and Wright, D and Kohner, E and Fox, C and Hadden, D and Mehta, Z and Smith, A and Nugent, Z and Peto, R and Adlel, AI and Mann, JI and Bassett, PA and Oakes, SF and Dornan, TL and Aldington, S and Lipinski, H and Collum, R and Harrison, K and MacIntyre, C and Skinner, S and Mortemore, A and Nelson, D and Cockley, S and Levien, S and Bodsworth, L and Willox, R and Biggs, T and Dove, S and Beattie, E and Gradwell, M and Staples, S and Lam, R and Taylor, F and Leung, L and Carter, RD and Brownlee, SM and Fisher, KE and Islam, K and Jelfs, R and Williams, PA and Williams, FA and Sutton, PJ and Ayres, A and Logie, LJ and Lovatt, C and Evans, MA and Stowell, LA and Ross, I and Kennedy, IA and Croft, D and Keen, AH and Rose, C and Raikou, M and Fletcher, AE and Bulpitt, C and Battersby, C and Yudkin, JS and Stevens, R and Stearn, MR and Palmer, SL and Hammersley, MS and Franklin, SL and Spivey, RS and Levy, JC and Tidy, CR and Bell, NJ and Steemson, J and Barrow, BA and Coster, R and Waring, K and Nolan, L and Truscott, E and Walravens, N and Cook, L and Lampard, H and Merle, C and Parker, P and McVittie, J and Draisey, I and Murchison, LE and Brunt, AHE and Williams, MJ and Pearson, DW and Petrie, XMP and Lean, MEJ and Walmsley, D and Lyall, F and Christie, E and Church, J and Thomson, E and Farrow, A and Stowers, JM and Stowers, M and McHardy, K and Patterson, N and Wright, AD and Levi, NA and Shearer, ACI and Thompson, RJW and Taylor, G and Rayton, S and Bradbury, M and Glover, A and Smyth-Osbourne, A and Parkes, C and Graham, J and England, P and Gyde, S and Eagle, C and Chakrabarti, B and Smith, J and Sherwell, J and Oakley, NW and Whitehead, MA and Hollier, GP and Pilkington, T and Simpson, J and Anderson, M and Martin, S and Kean, J and Rice, B and Rolland, A and Nisbet, J and Kohner, EM and Dornhorst, A and Doddridge, MC and Dumskyij, M and Walji, S and Sharp, P and Sleightholm, M and Vanterpool, G and Frost, G and Roseblade, M and Elliott, S and Forrester, S and Foster, M and Myers, K and Chapman, R and Hayes, JR and Henry, RW and Featherston, MS and Archbold, GPR and Copeland, M and Harper, R and Richardson, I and Davison, HA and Alexander, L and Scarpello, JHB and Shiers, DE and Tucker, RJ and Worthington, JRH and Angris, S and Bates, A and Walton, J and Teasdale, M and Browne, J and Stanley, S and Davis, BA and Strange, RC and Hadden, DR and Kennedy, L and Atkinson, AB and Bell, PM and McCance, DR and Rutherford, J and Culbert, AM and Hegan, C and Tennet, H and Webb, N and Robinson, I and Holmes, J and Nesbitt, S and Spathis, AS and Hyer, S and Nanson, ME and James, LM and Tyrell, JM and Davis, C and Strugnell, P and Booth, M and Petrie, H and Clark, D and Hulland, S and Barron, JL and Gould, BC and Singer, J and Badenoch, A and McGregor, M and Isenberg, L and Eckert, M and Alibhai, K and Marriot, E and Cox, C and Price, R and Fernandez, M and Ryle, A and Clarke, S and Wallace, G and Mehmed, E and Lankester, JA and Howard, E and Waite, A and MacFarlane, S and Greenwood, RH and Wilson, J and Denholm, MJ and Temple, RC and Whitfield, K and Johnson, F and Munroe, C and Gorick, S and Duckworth, E and Fatman, M and Rainbow, S and Borthwick, L and Wheatcroft, DJ and Seaman, RJ and Christie, RA and Wheatcroft, W and Musk, P and White, J and McDougal, S and Bond, M and Raniga, P and Day, JL and Doshi, MJ and Wilson, JG and Howard-Williams, JR and Humphreys, H and Graham, A and Hicks, K and Hexman, S and Bayliss, P and Pledger, D and Newton, RW and Jung, RT and Roxburgh, C and Kilgallon, B and Dick, L and Waugh, N and Kilby, S and Ellingford, A and Burns, J and Fox, CV and Holloway, MC and Coghill, HM and Hein, N and Fox, A and Cowan, W and Richard, M and Quested, K and Evans, SJ and Paisey, RB and Brown, NPR and Tucker, AJ and Paisey, R and Garrett, F and Hogg, J and Park, P and Williams, K and Harvey, P and Wilcocks, R and Mason, S and Frost, J and Warren, C and Rocket, P and Bower, L and Roland, JM and Brown, DJ and Youens, J and Stanton-King, K and Mungall, H and Ball, V and Maddison, W and Donnelly, D and King, S and Griffin, P and Smith, S and Church, S and Dunn, G and Wilson, A and Palmer, K and Brown, PM and Humphriss, D and Davidson, AJM and Rose, R and Armistead, L and Townsend, S and Poon, P and Peacock, IDA and Culverwell, NJC and Charlton, MH and Connolly, BPS and Peacock, J and Barrett, J and Wain, J and Beeston, W and King, G and Hill, PG and Boulton, AJM and Robertson, AM and Katoulis, V and Olukoga, A and McDonald, H and Kumar, S and Abouaesha, F and Abuaisha, B and Knowles, EA and Higgins, S and Booker, J and Sunter, J and Breislin, K and Parker, R and Raval, P and Curwell, J and Davenport, H and Shawcross, G and Prest, A and Grey, J and Cole, H and Sereviratne, C and Young, RJ and Clyne, JR and Gibson, M and O'Connell, I and Wong, LM and Wilson, SJ and Wright, KL and Wallace, C and McDowell, D and Burden, AC and Sellen, EM and Gregory, R and Roshan, M and Vaghela, N and Burden, M and Sherriff, C and Mansingh, S and Clarke, J and Grenfell, J and Tooke, JE and MacLeod, K and Seamark, C and Rammell, M and Pym, C and Stockman, J and Yeo, C and Piper, J and Leighton, L and Green, E and Hoyle, M and Jones, K and Hudson, A and James, AJ and Shore, A and Higham, A and Martin, B and Neil, HAW and Butterfield, WJH and Doll, WRS and Eastman, R and Ferris, FR and Kurinij, N and McPherson, K and Mahler, RF and Meade, TW and Shafer, G and Watkins, PJ and Keen, H and Siegel, D and Wright, AD and Betteridge, DJ and Cohen, RD and Currie, D and Darbyshire, J and Forrester, JV and Guppy, T and Johnston, DG and McGuire, A and Murphy, M and el-Nahas, AM and Pentecost, B and Spiegelhalter, D and Alberti, KGMM and Denton, R and Home, PD and Howell, S and Jarrett, JR and Marks, V and Marmot, M and Ward, JD and UK Prospective Diabet Study Grp, (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). LANCET , 352 (9131) 837 - 853.
Full text not available from this repository.
Abstract
Background Improved blood-glucose control decreases the progression of diabetic microvascular disease, but the effect on macrovascular complications is unknown. There is concern that sulphonylureas may increase cardiovascular mortality in patients with type 2 diabetes and that high insulin concentrations may enhance atheroma formation. We compared the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial.Methods 3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a mean of two fasting plasma glucose (FPG) concentrations of 6.1-15.0 mmol/L were randomly assigned intensive policy with a sulphonylurea (chlorpropamide, glibenclamide, or. glipizide) or with insulin, or conventional policy with diet. The aim in the intensive group was FPG less than 6 mmol/L. in the conventional group, the aim was the best achievable FPG with diet atone; drugs were added only if there were hyperglycaemic symptoms or FPG greater than 15 mmol/L. Three aggregate endpoints were used to assess differences between conventional and intensive treatment: any diabetes-related endpoint (sudden death, death from hyperglycaemia or hypoglycaemia, fatal or non-fatal myocardial infarction, angina, heart failure, stroke, renal failure, amputation [of at least one digit], vitreous haemorrhage, retinopathy requiring photocoagulation, blindness in one eye,or cataract extraction); diabetes-related death (death from myocardial infarction, stroke, peripheral vascular disease, renal disease, hyperglycaemia or hypoglycaemia, and sudden death); all-cause mortality. Single clinical endpoints and surrogate subclinical endpoints were also assessed. All analyses were by intention to treat and frequency of hypoglycaemia was also analysed by actual therapy.Findings Over 10 years, haemoglobin A(1c) (HbA(1c)) was 7.0% (6.2-8.2) in the intensive group compared with 7.9% (6.9-8.8) in the conventional group-an 11% reduction. There was no difference in HbA(1c) among agents in the intensive group. Compared with the conventional group, the risk in the intensive group was 12% lower (95% CI 1-21, p=0.029) for any diabetes-related endpoint; 10% lower (-11 to 27, p=0.34) for any diabetes-related death; and 6% lower (-10 to 20, p=0.44) for all-cause mortality. Most of the risk reduction in the any diabetes-related aggregate endpoint was due to a 25% risk reduction (7-40, p=0.0099) in microvascular endpoints, including the need for retinal photocoagulation. There was no difference for any of the three aggregate endpoints the three intensive agents (chlorpropamide, glibenclamide, or insulin).Patients in the intensive group had more hypoglycaemic episodes than those in the conventional group on both types of analysis (both p<0.0001). The rates of major hypoglycaemic episodes per year were 0.7% with conventional treatment, 1.0% with chlorpropamide, 1.4% with glibenclamide, and 1.8% with insulin. Weight gain was significantly higher in the intensive group (mean 2.9 kg) than in the conventional group (p<0.001), and patients assigned insulin had a greater gain in weight (4.0 kg) than those assigned chlorpropamide (2.6 kg) or glibenclamide (1.7 kg).Interpretation Intensive blood-glucose control by either sulphonylureas or insulin substantially decreases the risk of microvascular complications, but not macrovascular disease, in patients with type 2 diabetes. None of the individual drugs had an adverse effect on cardiovascular outcomes. All intensive treatment increased the risk of hypoglycaemia.
| Type: | Article |
|---|---|
| Title: | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) |
| Keywords: | MICROVASCULAR COMPLICATIONS, NIDDM PATIENTS, HEART-DISEASE, MELLITUS, THERAPY, SECONDARY, TRIAL |
| UCL classification: | UCL > School of Life and Medical Sciences |
Archive Staff Only: edit this record